29:19

Reducing burden of disease in gMG: Exploring the role of FcRn inhibitors

12:02

The potential of BTKi therapies in progressive forms of MS

32:32

Empowering T2D management: The evolution of basal insulin therapy

56:43

Navigating the clinical impact of TROP2-targeting in NSCLC

37:52

The evolving standard of care for advanced/recurrent endometrial cancer

34:42

Tailoring treatment in myelofibrosis: Addressing anaemia and thrombocytopenia

33:29

touchMDT ADCs in metastatic breast cancer: Managing toxicities and optimizing quality of life

17:43

Precision in practice: Adopting emerging therapies for retinal diseases to reduce burden of disease

36:13

PARP inhibitors for metastatic castration-resistant prostate cancer

30:15

The next frontier in managing obesity with or without T2D: The role of novel combinations

35:15

Cervical cancer prevention and beyond: Optimizing HPV vaccine uptake in all eligible individuals

15:41

Looking to the future in the treatment of steroid-refractory chronic GvHD

54:39

Updates in BCMA-directed therapies in multiple myeloma from ASH 2024

29:09

RAS mutations and personalized cancer care: Targeting the future

20:25

Focused insights: Data implications of ADCs in NSCLC treatment

01:19:57

Collaboration in chronic ITP: Improving quality of life and patient outcomes

35:50

Management of neurofibromatosis: Optimizing treatment and care from childhood to adult life

32:34

Navigating treatment choices in high-risk early-stage melanoma

35:54

Advancing the treatment of muscle-invasive bladder cancer

17:50

Supporting healing in epidermolysis bullosa: Innovations and new directions for care

33:48

Primary biliary cholangitis: Appraising the changing therapeutic landscape

39:16

Where to next in limited-stage small cell lung cancer? The role of immune checkpoint inhibitors

27:29

Precision targeting of MET in NSCLC: A multidisciplinary approach

32:03

Vaccination strategies for pneumococcal disease: Update and perspectives on clinical need and impact

50:02

Optimizing treatment of CML in the first-line setting and beyond

33:26

Pharmacological management of agitation in Alzheimer’s dementia

51:13

Multidisciplinary insights:Navigating the challenges of systemic mastocytosis diagnosis & management

55:13

Precision targeting of MET in NSCLC: A multidisciplinary approach

55:22

Targeting BCMA in multiple myeloma: Insights from COMy and EHA 2024

38:00

Navigating the management of cholestatic pruritus in patients with PBC

31:44

Innovations in glaucoma care: Targeting pathophysiology to expand treatment options

39:00

Treating moderate-to-severe atopic dermatitis in children and adolescents: Insights from the experts

40:57

Expanding HER2 horizons: Implications for NSCLC and beyond

31:53

Perspectives on EGFR-mutant and wildtype NSCLC: Tailoring treatment advances in late-stage disease

17:24

Updates in recurrent/metastatic nasopharyngeal carcinoma: The role of immune checkpoint inhibitors

51:31

Insights from EHA and ISTH 2024: How can we optimize care for patients with chronic ITP?

40:30

Continuous glucose monitoring in type 2 diabetes: Overcoming barriers to optimize outcomes

37:05

touchPANEL DISCUSSION Thyroid eye disease: An evolving continuum of care

15:09

touchFOCUS Expanding the reach of HER2 in solid tumours: A spotlight on tumour-agnostic approaches

38:53

Maximizing the possibilities in the evolving treatment paradigm for R/R follicular lymphoma

38:53

Maximizing the possibilities in the evolving treatment paradigm for R/R follicular lymphoma

37:05

Thyroid eye disease: An evolving continuum of care

15:09

Expanding the reach of HER2 in solid tumours: A spotlight on tumour-agnostic approaches

35:03

The path from detection to personalized long-term care for Fabry disease

35:27

Intracranial haemorrhage related to direct oral anticoagulant medications

38:07

Demystifying virology: The link between the HIV life cycle and ART

39:23

Knowledge for nurses: ADC updates in breast cancer

39:35

Early diagnosis and treatment of NMOSD: Practical insights

36:45

Decoding HER2 in NSCLC: Advances in biomarker testing and targeted therapies

47:43

Recognizing and managing HLH in the critical care setting: Best practice for the MD team

42:24

Let’s talk about agitation in Alzheimer’s dementia: reaching a diagnosis

32:52

Immunotherapy for early-stage, resectable NSCLC: From clinical trial data to guidelines

57:26

Navigating diagnosis, monitoring, and early treatment in achondroplasia: Multidisciplinary insights

30:33

Advanced urothelial carcinoma: Expert guidance to navigate an evolving therapeutic landscape

37:54

Clinical decision making with immunotherapies in advanced or recurrent endometrial cancer

30:29

Optimizing management of bronchiolitis obliterans syndrome: Current strategies, future directions

21:11

Harnessing the power of precision medicine for the treatment of colorectal cancer

21:18

Harnessing the power of precision medicine for the treatment of colorectal cancer

15:14

Current treatments and unmet needs in limited-stage small cell lung cancer

58:09

Multidisciplinary perspectives on management of agitation in Alzheimer’s dementia